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Background
Wk 24 TRANxITION study data showed patients tran-
sitioned from immediate release nevirapine (NVP IR)
twice daily (BID) to NVP extended release (NVP XR)
once-daily (QD) demonstrated non-inferior efficacy to
patients continuing on IR NVP BID [1]. Similar safety
was reported for NVP XR and NVP IR in the VERxVE
study [2]
2. Wk 48 efficacy/safety data from TRANxI-
TION study are presented here.
Methods
Open label, randomized (2:1), non-inferiority, parallel
group study comparing NVP XR 400 mg QD with NVP
IR 200 mg BID in HIV-1 patients >18 years receiving IR
NVP plus one of three NRTI combinations, with viral
load (VL) <50 copies/mL. Patients remained on their
previous background therapy for treatment duration.
Sustained virologic response (VL <50 copies/mL) was
assessed at Wk 48 using a time-to-loss of virologic
response (TLOVR) algorithm.
Results
426 patients completed 48 wks of treatment. 94.9% of
NVP XR and 91.9% of NVP IR patients. Mean baseline
CD4+ counts: 557.7 cells/mm
3 and 569.7 cells/mm
3,
respectively. 48 Wk data are reported in Table 1. Non-
inferiority of virologic suppression was achieved using a
TLOVR and snapshot analysis.
Conclusions
At Wk 48, non-inferiority between the NVP XR 400 mg
QD and NVP IR 200 mg BID groups was sustained. No
unexpected AEs were observed at Wk 48. These data
support transition from NVP IR to NVP XR in patients
stable on the former formulation.
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Table 1
Parameter NVP XR QD (N=295) IR NVP BID (N=148) Difference (95% CI)
Virologic response (VL <50 copies/mL, TLOVR-FAS), n (%) 261 (88.5) 130 (87.8) 0.6 (-5.9, 7.1)*
CD4+ count cells/mm3 (LOCF), mean (SD) 52.1 (140.5) 81.6 (138.2) -
AEs, n (%) 255 (86.4%) 108 (73.0%) -
DAIDS Grade 3-4 19 (6.4%) 9 (6.1%) -
SAEs, n (%)† 30 (10.2%) 12 (8.1%) -
*Based on Cochran’s statistic †None drug related, FAS = full analysis set; AE = adverse event; SAE = Serious adverse event
AEs were mostly mild-moderate in both groups with a higher reported rate of gastrointestinal AEs in XR. The proportion of patients with DAIDS Grade 3/4 AEs
was similar in the XR and IR groups.
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